Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.63 |
| ▸ | AVPR1A | P37288 | 14/20 | 0.68 |
| ▸ | OXTR | P30559 | 13/20 | 0.64 |
| ▸ | AVPR2 | P30518 | 12/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204681 | 0.99 | AVPR1A (0.69) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL1660631 | 0.91 | OXTR (0.76) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL5439053 | 0.87 | AVPR1A (0.70) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL20277836 | 0.80 | AVPR1A (0.81) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL6199829 | 0.80 | OXTR (0.90) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4840202 | 0.80 | AVPR1A (0.91) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL45247 | 0.79 | OXTR (0.59) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL6425099 | 0.78 | AVPR1A (0.88) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL19253308 | 0.78 | OXTR (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL31737128 | 0.78 | OXTR (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | claimed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | claimed |
| EP-2575853-B1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A FEEDING DISORDER WITH EARLY-ONSET IN A PATIENT | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-20160058830-A1 | Therapy and Prevention of Problem Drinking | THE UNIVERSITY OF SYDNEY (AU) | 2016-03-03 | — | — | US | disclosed |
| US-9125862-B2 | Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9119805-B2 | Therapy and prevention of problem drinking | THE UNIVERSITY OF SYDNEY (AU) | 2015-09-01 | — | — | US | disclosed |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8853158-B2 | Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2014-10-07 | — | — | US | disclosed |
| EP-2482835-B1 | THERAPY AND PREVENTION OF PROBLEM DRINKING | UNIV SYDNEY (AU) | 2014-07-02 | — | — | EP | disclosed |
| US-20130102528-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | CHU DE TOULOUSE (FR) | 2013-04-25 | — | — | US | disclosed |
| US-20120270785-A1 | Therapy and Prevention of Problem Drinking | THE UNIVERSITY OF SYDNEY (AU) | 2012-10-25 | — | — | US | disclosed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | CHRM3 492/4885AVPR1A 7/4885OXTR 1/4885 |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | CHRM3 465/4885AVPR1A 10/4885OXTR 1/4885 |
| US-20160058830-A1 | Therapy and Prevention of Problem Drinking | OXTR, AVPR1B, AVPR1A | CHRM3 114/4885AVPR1A 3/4885OXTR 1/4885 |
| US-20120270785-A1 | Therapy and Prevention of Problem Drinking | OXTR, AVPR1B, AVPR1A | CHRM3 114/4885AVPR1A 3/4885OXTR 1/4885 |
| US-20130102528-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | CHRM3 465/4885AVPR1A 10/4885OXTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.